Literature DB >> 2962478

Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome.

C L Grines1, E J Topol, E R Bates, J E Juni, J A Walton, W W O'Neill.   

Abstract

To determine the risk of arterial reocclusion or recurrent ischemia after acute intervention in myocardial infarction, we analyzed the results of coronary arteriography performed acutely and at 1 week in 50 consecutive patients who received acute intervention. Successful recanalization of the infarct vessel was achieved in 46 (92%) patients after therapy with intravenous tissue plasminogen activator, percutaneous coronary angioplasty, or both. Follow-up angiography in 44 showed early reocclusion in 10 patients (23%). Intermittent patency during acute arteriography was always associated with reocclusion; suboptimal (Thrombolysis in Myocardial Infarction [TIMI] class 2) flow was associated with a 50% rate of reocclusion. Although residual stenosis of greater than 50% alone was not predictive of rethrombosis, 90% of all reocclusions were associated with either stenosis greater than 50%, TIMI 2 flow, or intermittent patency. Absence of these angiographic risk factors predicted a 95% patency rate at follow-up. In-hospital cardiac complications occurred in 17 of 23 (74%) patients with residual stenosis of greater than 50% (death in four, ischemia in 13), and late revascularization was required in 53% of survivors. Only 15% of the group with less than 50% stenosis had an in-hospital ischemic event (p less than 0.001). Thus, after acute intervention, an infarct vessel with intermittent patency or suboptimal flow is associated with a high rate of reocclusion. Residual stenosis greater than or equal to 50% appears to predict a high incidence of negative in-hospital clinical outcomes and the need for subsequent revascularization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2962478     DOI: 10.1016/0002-8703(88)90510-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Atherosclerosis: past, present, and future.

Authors:  R J Hall
Journal:  Tex Heart Inst J       Date:  1990

3.  Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

4.  Percutaneous coronary intervention: recommendations for good practice and training.

Authors:  K D Dawkins; T Gershlick; M de Belder; A Chauhan; G Venn; P Schofield; D Smith; J Watkins; H H Gray
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

5.  ST variability during the first 4 hours of acute myocardial infarction predicts 1-year mortality.

Authors:  P Johanson; K Swedberg; M Dellborg
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-07       Impact factor: 1.468

6.  Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 7.  A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome.

Authors:  J Lespérance; P Théroux; G Hudon; D Waters
Journal:  Int J Card Imaging       Date:  1994-06

8.  Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure.

Authors:  Joerg Honold; Ulrich Fischer-Rasokat; Florian H Seeger; David Leistner; Saskia Lotz; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2013-04-24       Impact factor: 5.460

9.  Changes in myocardial echo amplitude during reversible ischaemia in humans.

Authors:  D A Lythall; D G Gibson; S S Kushwaha; M S Norell; A G Mitchell; C J Ilsley
Journal:  Br Heart J       Date:  1992-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.